NCT02373124View on ClinicalTrials.gov

Glutamatergic Modulation of Motivation Enhancement: A Pilot Feasibility Trial

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Cocaine Use Disorders
Interventions
DRUG

infusion of NMDA antagonist

52 minute infusion

Trial Locations (1)

10032

New York State Psychiatric Institute, New York

All Listed Sponsors
lead

New York State Psychiatric Institute

OTHER

NCT02373124 - Glutamatergic Modulation of Motivation Enhancement: A Pilot Feasibility Trial | Biotech Hunter | Biotech Hunter